Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk (NVO), maker of popular weight-loss drugs Ozempic and Wegovy, is set to report third-quarter earnings Wednesday morning, with Wall Street analysts generally bullish on the Danish drugmaker's stock.

What Wall Street Analysts Think of Novo Nordisk's Stock Ahead of Earnings

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Wall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?

NVO's third-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.

Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?

Airbnb

Marriott

Ferrari

Super Micro Computer

U.S. Election Day, a Federal Reserve meeting, and earnings reports from around 100 S&P 500 companies.

Super Micro, Ferrari, Marriott, Airbnb, Novo Nordisk, and More Stocks to Watch This Week

Novo Nordisk (NYSE:NVO) has reported another successful trial for its Wegovy or  Semaglutide drug, this time in the treatment of fibrosis caused by the fatty liver condition known as MASH. Headline results from part 1 of the ongoing ESSENCE trial, a phase three, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis, showed it met its primary endpoint, Compared to placebo there was a statistically significant and superior improvement in liver fibrosis with no worsening of steatohepatitis, said the Danish group which is Europe's largest company.

Wegovy effective in MASH fatty liver fibrosis trial says Novo

Novo Nordisk said on Friday its weight-loss drug Wegovy met the main goal of a late-stage trial by showing improvement in liver fibrosis with no worsening of steatohepatitis.

Novo's Wegovy helps improve liver fibrosis in late-stage trial

Bagsværd, Denmark, 1 November 2024 – Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis (stage 2 or 3)1. Part 1 of the ESSENCE trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue (histology) compared to placebo on top of standard of care for the first 800 randomised people at 72 weeks.

Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial

Novo Nordisk's drug helped reduce knee pain in osteoarthritis patients with obesity. Meanwhile, the Change Healthcare breach hit at least 100 million Americans.

Healthy Returns: Wegovy may reduce knee pain in patients with a type of arthritis and obesity

All doses of Novo Nordisk's weight loss injection Wegovy and diabetes drug Ozempic are now available in the U.S., according to an update on the FDA's drug shortage database. It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to skyrocket in the U.S.

Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says

The lowest dose of Novo Nordisk's weight-loss drug, Wegovy, was listed as available, the U.S. health regulator's website showed on Wednesday.

US FDA says lowest dose of Novo Nordisk's weight-loss drug now available

Apple

Raytheon Technologies

Apple, Novo Nordisk, RTX and FONAR are included in this Analyst Blog.

The Zacks Analyst Blog Apple, Novo Nordisk, RTX and FONAR

Eli Lilly

One key disease-prevention market is drawing closer to being within reach.

1 Huge New Reason to Buy Eli Lilly or Novo Nordisk Stock Right Now and Hold It Forever

In the latest trading session, Novo Nordisk (NVO) closed at $112.46, marking a -0.82% move from the previous day.

Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know

SAN FRANCISCO--(BUSINESS WIRE)--Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates.

Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates

Novo Nordisk just released data from a clinical trial featuring its oral semaglutide treatment, Rybelsus.

This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic)

Catalent

Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the acquisition, especially in weight-loss drug manufacturing.

CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases

Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition to the home country of its biggest weight-loss rival, Danish pharmaceuticals group Novo Nordisk.

Lilly to launch its obesity drug in Denmark, Novo Nordisk's home market

Novo Nordisk's blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer's disease, according to a new analysis of electronic health records. The findings suggest that Ozempic and other GLP-1 treatments could potentially delay or prevent the memory-robbing condition in patients with diabetes.

Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says

Novo Nordisk on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat versions of its popular weight-loss and diabetes drugs, which it said were too complex for those manufacturers to produce safely.

Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies

Novo Nordisk A/S NVO just hit a technical red flag — a Death Cross.

Novo Nordisk's Death Cross: Is A Turnaround Coming For The Ozempic, Wegovy Maker?

Novo Nordisk asked the Food and Drug Administration to prevent compounding pharmacies from making cheaper versions of its popular weight loss injection Wegovy and diabetes treatment Ozempic. The Danish drugmaker argues that the medications are too complex for those manufacturers to make safely.

Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies

Novo Nordisk (NVO) closed at $116.47 in the latest trading session, marking a -0.73% move from the prior day.

Why Novo Nordisk (NVO) Dipped More Than Broader Market Today

A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients compared to placebo.

NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients

Biogen

Novartis

Pfizer

Regeneron Pharmaceuticals

Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings.

News for Novo Nordisk Stock (NVO)